Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 275 of 385 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/10/22
End: 06/10/25
Due: 06/10/26
Phase: N/A
Priority: Normal
Start: 07/02/21
End: 07/01/23
Due: 07/01/24
Phase: N/A
Priority: Normal
Start: 07/31/19
End: 07/31/25
Due: 07/31/26
Phase: N/A
Priority: Normal
Start: 08/01/24
End: 01/31/26
Due: 01/31/27
Phase: N/A
Priority: Normal
Start: 10/10/20
End: 04/01/24
Due: 04/01/25
Phase: N/A
Priority: Normal
Start: 03/31/24
End: 12/31/35
Due: 12/31/36
Phase: N/A
Priority: Normal
Start: 08/01/24
End: 01/01/33
Due: 01/01/34
Phase: N/A
Priority: Normal
Start: 03/01/24
End: 04/01/25
Due: 04/01/26
Phase: N/A
Priority: Normal
Start: 11/01/20
End: 12/01/23
Due: 12/01/24
Phase: N/A
Priority: Normal
Start: 08/01/23
End: 07/31/25
Due: 07/31/26
Phase: N/A
Priority: Normal
Start: 05/31/14
End: 05/31/26
Due: 05/31/27
Phase: N/A
Priority: Normal
Start: 07/26/24
End: 06/30/27
Due: 06/30/28
Phase: N/A
Priority: Normal
Start: 01/16/25
End: 05/16/30
Due: 05/16/31
Phase: N/A
Priority: Normal
Start: 07/13/21
End: 03/31/28
Due: 03/31/29
Phase: N/A
Priority: Normal
Start: 04/01/19
End: 04/21/23
Due: 04/21/24
Phase: N/A
Priority: Normal
Start: 02/16/23
End: 02/16/30
Due: 02/16/31
Phase: N/A
Priority: Normal
Start: 02/02/23
End: 02/02/24
Due: 02/02/25
Phase: N/A
Priority: Normal
Start: 06/01/25
End: 12/01/27
Due: 12/01/28
Phase: N/A
Priority: Normal
Start: 01/01/25
End: 06/01/27
Due: 06/01/28
Phase: N/A
Priority: Normal
Start: 01/03/24
End: 12/31/26
Due: 12/31/27
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Phase: N/A
Priority: Normal
Start: 02/25/22
End: 02/25/25
Due: 02/25/26
Phase: N/A
Priority: Normal
Start: 03/11/24
End: 09/01/26
Due: 09/01/27
Phase: N/A
Priority: Normal
Start: 11/30/23
End: 06/30/24
Due: 06/30/25
Phase: N/A
Priority: Normal
Start: 08/20/24
End: 07/07/26
Due: 07/07/27
Phase: N/A
Priority: Normal
Start: 05/31/25
End: 12/31/27
Due: 12/31/28